3 results
The primary objective of this study is to assess whether abelacimab is non-inferior to dalteparin for preventing VTE recurrence through 6 monthspost randomization in patients with GI or GU cancer and recently diagnosed VTE. If non-inferiority is…
Primary, to show that a single intravesical instillation of chemotherapy immediately before radical surgery for an upper urinary tract (UUT) urothelial carcinoma leads to a 40% reduction in the risk of a subsequent bladder recurrence (urothelial…
The primary objective of this study is to assess whether abelacimab is non-inferior to apixaban for preventing VTE recurrence at 6 months postrandomization in patients with cancer and recently diagnosed VTE. If noninferiority is demonstrated, then…